Sutro Biopharma Cash Flow-to-Debt Ratio
Sutro Biopharma cash flow-to-debt ratio. Sutro Biopharma (STRO) has a Cash Flow-to-Debt Ratio of -0.13x as of June 2026, meaning its operating cash flow of $-38.29 Million could theoretically repay 0% of its total liabilities ($297.78 Million) in one year. Check STRO cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Sutro Biopharma (2016–2025)
Cash flow-to-debt ratio of Sutro Biopharma from 2016 to 2025. Historical debt coverage capacity for Sutro Biopharma across 10 annual periods. Check Sutro Biopharma investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Sutro Biopharma Cash Flow-to-Debt Ratio by Year (2016–2025)
Sutro Biopharma cash flow-to-debt ratio by year from 2016 to 2025. Year-by-year debt coverage analysis for Sutro Biopharma. For the full cash flow conversion analysis, see Sutro Biopharma cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.58x | $-177.23 Million | $306.28 Million | ▼ -3.5% |
| 2024 | -0.56x | $-191.54 Million | $342.61 Million | ▼ -60.8% |
| 2023 | -0.35x | $-111.62 Million | $321.09 Million | ▼ -1960.0% |
| 2022 | 0.02x | $3.55 Million | $189.90 Million | ▲ +102.0% |
| 2021 | -0.92x | $-81.68 Million | $88.84 Million | ▲ +15.8% |
| 2020 | -1.09x | $-67.80 Million | $62.06 Million | ▲ +1.6% |
| 2019 | -1.11x | $-65.02 Million | $58.58 Million | ▼ -901.6% |
| 2018 | 0.14x | $12.68 Million | $91.60 Million | ▲ +155.9% |
| 2017 | -0.25x | $-37.07 Million | $149.77 Million | ▼ -201.5% |
| 2016 | -0.08x | $-13.15 Million | $160.18 Million | — |